Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1626 1629 1681
This examiner grants 77% of resolved cases
Kevin Stephen Martin has resolved 158 cases in Art Unit 1624 of Tech Center 1600. His allowance rate is 77.2 percent. This percentage is a primary metric for practitioners to consider when evaluating the examiner's history. The data also shows an interview lift of 23.2 percent. This 23.2 percent lift indicates the change in allowance probability associated with an interview.
The median days to allowance is 1257. This 1257-day figure represents the duration of the prosecution process for cases that reach a grant. Practitioners should consider the 158 resolved cases as a historical record of the examiner's work. The 77.2 percent allowance rate and 23.2 percent interview lift are components of the examination profile. The median pendency is a factor for managing client expectations.
Direct communication is a documented tactic, as shown by the lift. Applicants should review the allowance rate as they prepare their prosecution strategy. The cases provide a data set for understanding the examiner's approach in Tech Center 1600. The timeline is a measure of the time required to navigate Art Unit 1624 to a successful conclusion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18698664 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | Final Rejection | Genentech, Inc. |
| 18251111 | CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Final Rejection | LG CHEM, LTD. |
| 18694139 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | Non-Final OA | The Regents of the University of California |
| 18255767 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | Final Rejection | The Johns Hopkins University |
| 18836154 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18556226 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18860849 | N-OXIDE COMPOUNDS AND USE THEREOF | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18570473 | CHIRAL 3-SULFINYL BENZOIC ACIDS | Final Rejection | BAYER AKTIENGESELLSCHAFT |
| 17596491 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | Final Rejection | The Governors of the University of Alberta |
| 18899540 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18818487 | SOLID FORMS OF FXR AGONISTS | Non-Final OA | Gilead Sciences, Inc. |
| 18041072 | METHODS FOR MAKING DARUNAVIR P2-LIGAND PRECURSORS | Non-Final OA | Purdue Research Foundation |
| 18568756 | PERIODATE COMPOSITIONS AND METHODS FOR CHEMICAL CLEAVAGE OF SURFACE-BOUND POLYNUCLEOTIDES | Non-Final OA | ILLUMINA, INC. |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18710715 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | Non-Final OA | BLUEPRINT MEDICINES CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy